{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T16:56:45Z","timestamp":1794589005542,"version":"4.9.1"},"reference-count":43,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinicaltherapeutics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.clinthera.2026.03.011","type":"journal-article","created":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T20:03:22Z","timestamp":1775851402000},"page":"462-470","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Pharmacological Management of Dry Eye Disease: A Contemporary Landscape Analysis"],"prefix":"10.1016","volume":"48","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-1134-0324","authenticated-orcid":false,"given":"Chenxuan","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-3053-4158","authenticated-orcid":false,"given":"Junyi","family":"Lou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-0701-9765","authenticated-orcid":false,"given":"Lin","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-7771-4623","authenticated-orcid":false,"given":"Zining","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-0741-2900","authenticated-orcid":false,"given":"Runze","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-9224-1833","authenticated-orcid":false,"given":"Zongwei","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-4214-1246","authenticated-orcid":false,"given":"Jiahao","family":"Niu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0097-684X","authenticated-orcid":false,"given":"Xuan","family":"Liao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2026.03.011_bib0001","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.jtos.2024.11.004","article-title":"Cell death pathways in dry eye disease: insights into ocular surface inflammation","volume":"34","author":"Li","year":"2024","journal-title":"Ocul Surf"},{"issue":"10","key":"10.1016\/j.clinthera.2026.03.011_bib0002","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1089\/jop.2024.0103","article-title":"Inflammation in dry eye disease: pathogenesis, preclinical animal models, and treatments","volume":"40","author":"Bhujbal","year":"2024","journal-title":"J Ocul Pharmacol Ther"},{"key":"10.1016\/j.clinthera.2026.03.011_bib0003","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.jtos.2021.03.006","article-title":"Human precorneal tear film and lipid layer dynamics in meibomian gland dysfunction","volume":"21","author":"Bai","year":"2021","journal-title":"Ocul Surf"},{"key":"10.1016\/j.clinthera.2026.03.011_bib0004","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.ajo.2022.09.009","article-title":"Meibomian gland dysfunction: a route of ocular graft-versus-host disease progression that drives a vicious cycle of ocular surface inflammatory damage","volume":"247","author":"Perez","year":"2023","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.clinthera.2026.03.011_bib0005","article-title":"Meibomian gland dysfunction in Sj\u00f6gren\u2019s disease","volume":"12","author":"Anuwa-Amarh","year":"2025","journal-title":"Front Med (Lausanne)"},{"key":"10.1016\/j.clinthera.2026.03.011_bib0006","doi-asserted-by":"crossref","first-page":"93","DOI":"10.2147\/OPTH.S481124","article-title":"Epidemiology, tear film, and meibomian gland dysfunction in facial palsy: a comparative analysis","volume":"19","author":"Guerrero-de Ferran","year":"2025","journal-title":"Clin Ophthalmol"},{"key":"10.1016\/j.clinthera.2026.03.011_bib0007","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.exer.2017.02.008","article-title":"Meibocyte differentiation and renewal: insights into novel mechanisms of meibomian gland dysfunction (MGD)","volume":"163","author":"Hwang","year":"2017","journal-title":"Exp Eye Res"},{"issue":"9","key":"10.1016\/j.clinthera.2026.03.011_bib0008","article-title":"Climate change and its impact on ocular health: a systematic review","volume":"17","author":"Onyeze","year":"2025","journal-title":"Cureus"},{"issue":"2","key":"10.1016\/j.clinthera.2026.03.011_bib0009","doi-asserted-by":"crossref","first-page":"131","DOI":"10.4103\/1319-4534.337849","article-title":"Dry eye syndrome risk factors: a systematic review","volume":"35","author":"Hasan","year":"2022","journal-title":"Saudi J Ophthalmol"},{"issue":"3","key":"10.1016\/j.clinthera.2026.03.011_bib0010","doi-asserted-by":"crossref","first-page":"460","DOI":"10.3390\/medicina61030460","article-title":"Overview of dry eye disease for primary care physicians","volume":"61","author":"Kwon","year":"2025","journal-title":"Medicina (Kaunas)"},{"key":"10.1016\/j.clinthera.2026.03.011_bib0011","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/j.jtos.2025.07.010","article-title":"Topical pharmacologic treatments for dry eye disease: a systematic review","volume":"38","author":"Tong","year":"2025","journal-title":"Ocul Surf"},{"issue":"6","key":"10.1016\/j.clinthera.2026.03.011_bib0012","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1007\/s40271-022-00586-8","article-title":"Patient medication preferences for managing dry eye disease: the importance of medication side effects","volume":"15","author":"Ozdemir","year":"2022","journal-title":"Patient"},{"issue":"12","key":"10.1016\/j.clinthera.2026.03.011_bib0013","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1016\/j.molmed.2015.10.001","article-title":"Lipid-based therapy for ocular surface inflammation and disease","volume":"21","author":"Lim","year":"2015","journal-title":"Trends Mol Med"},{"key":"10.1016\/j.clinthera.2026.03.011_bib0014","doi-asserted-by":"crossref","first-page":"2565","DOI":"10.2147\/OPTH.S536742","article-title":"Reduced ocular surface inflammation in SMILE patients: the beneficial outcome of 0.1% ciclosporin cationic emulsion treatment","volume":"19","author":"Ng","year":"2025","journal-title":"Clin Ophthalmol"},{"issue":"2","key":"10.1016\/j.clinthera.2026.03.011_bib0015","doi-asserted-by":"crossref","first-page":"195","DOI":"10.5114\/ceji.2016.60995","article-title":"Immunomodulation on the ocular surface: a review","volume":"41","author":"Ambroziak","year":"2016","journal-title":"Cent Eur J Immunol"},{"issue":"4","key":"10.1016\/j.clinthera.2026.03.011_bib0016","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1097\/ICL.0000000000001076","article-title":"Novel management of ocular surface inflammation in patients with ocular graft-versus-host disease in the setting of cataract surgery","volume":"50","author":"Roca","year":"2024","journal-title":"Eye Contact Lens"},{"issue":"5","key":"10.1016\/j.clinthera.2026.03.011_bib0017","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1097\/ACI.0000000000000673","article-title":"Flavonoid and cannabinoid impact on the ocular surface","volume":"20","author":"Bielory","year":"2020","journal-title":"Curr Opin Allergy Clin Immunol"},{"key":"10.1016\/j.clinthera.2026.03.011_bib0018","doi-asserted-by":"crossref","DOI":"10.1016\/j.mehy.2020.110137","article-title":"Malassezia species may play potential roles in the pathogenesis of meibomian gland dysfunction","volume":"144","author":"Wang","year":"2020","journal-title":"Med Hypotheses"},{"issue":"8","key":"10.1016\/j.clinthera.2026.03.011_bib0019","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1056\/NEJMoa2308917","article-title":"CD19 CAR T-cell therapy in autoimmune disease: a case series with follow-up","volume":"390","author":"M\u00fcller","year":"2024","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.clinthera.2026.03.011_bib0020","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.mucimm.2024.11.002","article-title":"Activation of \u03b12B\/2C adrenergic receptor ameliorates ocular surface inflammation through enhancing regulatory T cell function","volume":"18","author":"Fan","year":"2025","journal-title":"Mucosal Immunol"},{"issue":"21","key":"10.1016\/j.clinthera.2026.03.011_bib0021","doi-asserted-by":"crossref","DOI":"10.3390\/ijms222111820","article-title":"Autoimmune epithelitis and chronic inflammation in Sj\u00f6gren\u2019s syndrome-related dry eye disease","volume":"22","author":"Ogawa","year":"2021","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.clinthera.2026.03.011_bib0022","doi-asserted-by":"crossref","first-page":"125","DOI":"10.2147\/OPTH.S126668","article-title":"Dry eye syndrome: developments and lifitegrast in perspective","volume":"12","author":"Lollett","year":"2018","journal-title":"Clin Ophthalmol"},{"key":"10.1016\/j.clinthera.2026.03.011_bib0023","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.2147\/OPTH.S110557","article-title":"Development of lifitegrast: a novel T-cell inhibitor for the treatment of dry eye disease","volume":"10","author":"Semba","year":"2016","journal-title":"Clin Ophthalmol"},{"issue":"3","key":"10.1016\/j.clinthera.2026.03.011_bib0024","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/j.alit.2025.05.003","article-title":"Updates on the ocular manifestations and treatment of SJS\/TEN","volume":"74","author":"Sotozono","year":"2025","journal-title":"Allergol Int"},{"issue":"4","key":"10.1016\/j.clinthera.2026.03.011_bib0025","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1089\/jop.2020.0087","article-title":"A randomized double-masked phase 2a trial to evaluate activity and safety of topical ocular reproxalap, a novel RASP inhibitor, in dry eye disease","volume":"37","author":"Clark","year":"2021","journal-title":"J Ocul Pharmacol Ther"},{"key":"10.1016\/j.clinthera.2026.03.011_bib0026","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.ajo.2021.01.011","article-title":"Early onset and broad activity of reproxalap in a randomized, double-masked, vehicle-controlled phase 2b trial in dry eye disease","volume":"226","author":"Clark","year":"2021","journal-title":"Am J Ophthalmol"},{"issue":"1","key":"10.1016\/j.clinthera.2026.03.011_bib0027","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/s12348-025-00497-3","article-title":"Reproxalap in patients with seasonal allergic conjunctivitis: a systematic review and meta-analysis","volume":"15","author":"Elgadi","year":"2025","journal-title":"J Ophthalmic Inflamm Infect"},{"issue":"4","key":"10.1016\/j.clinthera.2026.03.011_bib0028","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1007\/s40123-022-00520-z","article-title":"Reproxalap activity and estimation of clinically relevant thresholds for ocular itching and redness in a randomized allergic conjunctivitis field trial","volume":"11","author":"Cavanagh","year":"2022","journal-title":"Ophthalmol Ther"},{"issue":"2","key":"10.1016\/j.clinthera.2026.03.011_bib0029","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1080\/08820538.2025.2536766","article-title":"Recent advances in targeted immunomodulatory therapies for chronic ocular surface diseases","volume":"41","author":"Genovese","year":"2026","journal-title":"Semin Ophthalmol"},{"issue":"7","key":"10.1016\/j.clinthera.2026.03.011_bib0030","article-title":"Dry eye disease: oxidative stress on ocular surface and cutting-edge antioxidants","volume":"9","author":"Hu","year":"2025","journal-title":"Glob Chall"},{"key":"10.1016\/j.clinthera.2026.03.011_bib0031","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jconrel.2023.11.021","article-title":"Mitochondria-targeted SkQ1 nanoparticles for dry eye disease: inhibiting NLRP3 inflammasome activation by preventing mitochondrial DNA oxidation","volume":"365","author":"Huang","year":"2024","journal-title":"J Control Release"},{"key":"10.1016\/j.clinthera.2026.03.011_bib0032","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/B978-0-12-394625-6.00010-6","article-title":"Advances in development of rechargeable mitochondrial antioxidants","volume":"127","author":"Lukashev","year":"2014","journal-title":"Prog Mol Biol Transl Sci"},{"issue":"12","key":"10.1016\/j.clinthera.2026.03.011_bib0033","first-page":"968","article-title":"Chinese expert consensus on the diagnosis and treatment of dry eye (2024)","volume":"60","year":"2024","journal-title":"Zhonghua Yan Ke Za Zhi"},{"issue":"4","key":"10.1016\/j.clinthera.2026.03.011_bib0034","doi-asserted-by":"crossref","first-page":"P1","DOI":"10.1016\/j.ophtha.2023.12.041","article-title":"Dry eye syndrome preferred practice pattern\u00ae","volume":"131","author":"Amescua","year":"2024","journal-title":"Ophthalmology"},{"issue":"3","key":"10.1016\/j.clinthera.2026.03.011_bib0035","doi-asserted-by":"crossref","DOI":"10.1016\/j.clae.2025.102383","article-title":"Rodent models for dry eye syndrome (DES)","volume":"48","author":"Zhu","year":"2025","journal-title":"Cont Lens Anterior Eye"},{"issue":"9","key":"10.1016\/j.clinthera.2026.03.011_bib0036","article-title":"Topical cyclosporine A therapy for dry eye syndrome","volume":"9","author":"de Paiva","year":"2019","journal-title":"Cochrane Database Syst Rev"},{"issue":"1","key":"10.1016\/j.clinthera.2026.03.011_bib0037","doi-asserted-by":"crossref","DOI":"10.1136\/bmjophth-2020-000697","article-title":"Dry eye: why artificial tears are not always the answer","volume":"6","author":"Kim","year":"2021","journal-title":"BMJ Open Ophthalmol"},{"issue":"4","key":"10.1016\/j.clinthera.2026.03.011_bib0038","doi-asserted-by":"crossref","first-page":"422","DOI":"10.3390\/antiox13040422","article-title":"Potential new target for dry eye disease-oxidative stress","volume":"13","author":"Bu","year":"2024","journal-title":"Antioxidants (Basel)"},{"issue":"6","key":"10.1016\/j.clinthera.2026.03.011_bib0039","doi-asserted-by":"crossref","first-page":"e346","DOI":"10.1111\/aos.17486","article-title":"A narrative literature review about alpha-lipoic acid role in dry eye and ocular surface disease","volume":"103","author":"Mateo Orobia","year":"2025","journal-title":"Acta Ophthalmol"},{"issue":"12","key":"10.1016\/j.clinthera.2026.03.011_bib0040","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1167\/iovs.66.12.50","article-title":"Kaempferol alleviates dry eye disease via modulation of the IDH3B\/CCAR2\/IKBKB axis","volume":"66","author":"Zhang","year":"2025","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"1","key":"10.1016\/j.clinthera.2026.03.011_bib0041","doi-asserted-by":"crossref","first-page":"38","DOI":"10.3390\/ph18010038","article-title":"Therapeutic potential of combined 5% lifitegrast and tocopherol eye drops in managing inflammation and oxidative stress in murine dry eye","volume":"18","author":"Moon","year":"2025","journal-title":"Pharmaceuticals (Basel)"},{"issue":"7","key":"10.1016\/j.clinthera.2026.03.011_bib0042","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbadis.2025.167911","article-title":"Deficiency of antioxidant enzyme PRDX6 and mucosal chemokine CXCL17: unraveling the factors behind oxidative stress and mucosal homeostasis disruption in dry eye disease","volume":"1871","author":"Akkurt Arslan","year":"2025","journal-title":"Biochim Biophys Acta Mol Basis Dis"},{"issue":"2","key":"10.1016\/j.clinthera.2026.03.011_bib0043","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1167\/iovs.66.2.69","article-title":"Disruption in autonomic nervous activity is associated with central and peripheral-level in dry eye with unstable tear film","volume":"66","author":"Kaido","year":"2025","journal-title":"Invest Ophthalmol Vis Sci"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291826000731?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291826000731?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T08:34:39Z","timestamp":1782376479000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291826000731"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":43,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["S0149291826000731"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2026.03.011","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pharmacological Management of Dry Eye Disease: A Contemporary Landscape Analysis","name":"articletitle","label":"Article Title"},{"value":"Clinical Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinthera.2026.03.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc.","name":"copyright","label":"Copyright"}]}}